{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:41:41Z","timestamp":1792759301508,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ard.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:53:01Z","timestamp":1792756381000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging drugs in phase 2\/3 and selected phase 1\/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment"],"prefix":"10.1016","author":[{"given":"Eisha","family":"Naveed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Pauling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Del","family":"Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"McMahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg H.W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Suen","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.ard.2026.09.015_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0002","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.09.015_bib0003","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ard.2026.09.015_bib0005","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","volume":"85","author":"Antoniou","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard-2024-226429","article-title":"Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis","volume":"84","author":"Lescoat","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.09.015_bib0009","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41584-026-01416-z","article-title":"Navigating evidence-based recommendations for the management of systemic sclerosis","volume":"22","author":"Del Galdo","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.09.015_bib0010","article-title":"Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis","volume":"12","author":"Gavriilaki","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.ard.2026.09.015_bib0011","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ard.2026.09.015_bib0012","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00281-025-01065-6","article-title":"Systemic sclerosis: pathogenic mechanisms and their implications for treatment","volume":"47","author":"Lescoat","year":"2025","journal-title":"Semin Immunopathol"},{"issue":"3","key":"10.1016\/j.ard.2026.09.015_bib0014","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.09.015_bib0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0016","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ard.2026.09.015_bib0017","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","article-title":"Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma","volume":"59","author":"Yaseen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005903","article-title":"The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae098","article-title":"The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies","volume":"219","author":"Scaletti","year":"2025","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","article-title":"Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts","volume":"20","author":"Raschi","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ard.2026.09.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103016","article-title":"Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases","volume":"21","author":"Chalayer","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.ard.2026.09.015_bib0022","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/art.41243","article-title":"Profibrotic activation of human macrophages in systemic sclerosis","volume":"72","author":"Bhandari","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2026.09.015_bib0023","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.09.015_bib0024","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","article-title":"Fibrosis\u2013a lethal component of systemic sclerosis","volume":"10","author":"Ho","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.09.015_bib0025","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1007\/s10067-024-07123-y","article-title":"Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review","volume":"43","author":"Bazs\u00f3","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0026","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2025.201663","article-title":"Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial","volume":"34","author":"Nunez","year":"2026","journal-title":"Mol Ther Adv"},{"key":"10.1016\/j.ard.2026.09.015_bib0028","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1038\/s41467-026-72817-7","article-title":"Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells","volume":"17","author":"Rius Rigau","year":"2026","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0029","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/2643-3230.BCD-25-0262","article-title":"Clinical and cytokine features of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"7","author":"Srinagesh","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.ard.2026.09.015_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1461102","article-title":"CAR immunotherapy in autoimmune diseases: promises and challenges","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.ard.2026.09.015_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ard.2026.09.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ard.2026.09.015_bib0033","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.09.015_bib0034","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.09.015_bib0035","doi-asserted-by":"crossref","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance","volume":"4","author":"Matsushita","year":"2018","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0036","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.09.015_bib0037","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.09.015_bib0038","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.43059","article-title":"Safety and efficacy of Ianalumab in patients with Sj\u00f6gren's disease: 52-week results from a randomized, placebo-controlled, phase 2b dose-ranging study","volume":"77","author":"D\u00f6rner","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.09.015_bib0039","unstructured":"Grader-Beck T, Mariette X, Finzel S, Schiopu E, Papas A, Devauchelle-Pensec V, et al. Ianalumab demonstrates significant reduction in disease activity in patients with Sj\u00f6gren\u2019s disease: efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2). ACR Convergence 2025; October 24-29, 2025; Chicago, IL, USA. Abstract LB24."},{"key":"10.1016\/j.ard.2026.09.015_bib0040","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.2147\/DDDT.S493923","article-title":"The latest progress in the application of telitacicept in autoimmune diseases","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.ard.2026.09.015_bib0041","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"15","key":"10.1016\/j.ard.2026.09.015_bib0042","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0043","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/pathogens12060817","article-title":"Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker","volume":"12","author":"Zhou","year":"2023","journal-title":"Pathogens"},{"issue":"10","key":"10.1016\/j.ard.2026.09.015_bib0044","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ard.2026.09.015_bib0045","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: a review in generalised myasthenia gravis","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ard.2026.09.015_bib0046","article-title":"Role of TL1A in Inflammatory autoimmune diseases: a comprehensive review","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.09.015_bib0047","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/258164","article-title":"The role of TL1A and DR3 in autoimmune and inflammatory diseases","volume":"2013","author":"Aiba","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.ard.2026.09.015_bib0048","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.4049\/jimmunol.2000665","article-title":"TL1A promotes lung tissue fibrosis and airway remodeling","volume":"205","author":"Herro","year":"2020","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0049","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s10067-017-3612-y","article-title":"Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis","volume":"36","author":"Xu","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2026.09.015_bib0050","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.3390\/ijms26115017","article-title":"TL1A as a Target in Inflammatory bowel disease: exploring mechanisms and therapeutic potential","volume":"26","author":"Tettoni","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.ard.2026.09.015_bib0051","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of Anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0052","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdermsci.2025.01.002","article-title":"Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis","volume":"117","author":"Steadman","year":"2025","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0053","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0054","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2665-9913(24)00403-X","article-title":"Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study","volume":"7","author":"Hinchcliff","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2026.09.015_bib0055","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.43120","article-title":"Serum type I interferon score for prediction of clinically meaningful disease progression in limited cutaneous systemic sclerosis","volume":"77","author":"Di Donato","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0056","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A Randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0057","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ard.2026.09.015_bib0058","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00154-2019","article-title":"IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis","volume":"54","author":"Birnhuber","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0059","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12931-016-0475-8","article-title":"Pleural inhibition of the caspase-1\/IL-1\u03b2 pathway diminishes profibrotic lung toxicity of bleomycin","volume":"17","author":"Burgy","year":"2016","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.ard.2026.09.015_bib0060","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/art.39817","article-title":"Platelets induce thymic stromal lymphopoietin production by endothelial cells: contribution to fibrosis in human systemic sclerosis","volume":"68","author":"Truchetet","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2026.09.015_bib0061","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.09.015_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.08.003","article-title":"B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis","volume":"56","author":"Fran\u00e7ois","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ard.2026.09.015_bib0063","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system","volume":"90","author":"Schellenburg","year":"2017","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0064","article-title":"Efzofitimod: a novel anti-inflammatory agent for sarcoidosis","volume":"40","author":"Baughman","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"789","key":"10.1016\/j.ard.2026.09.015_bib0065","doi-asserted-by":"crossref","first-page":"eadp4754","DOI":"10.1126\/scitranslmed.adp4754","article-title":"A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis","volume":"17","author":"Nangle","year":"2025","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ard.2026.09.015_bib0066","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the Treatment of Pulmonary Sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.ard.2026.09.015_bib0067","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","article-title":"Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein","volume":"289","author":"O'Reilly","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ard.2026.09.015_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109723","article-title":"Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis","volume":"116","author":"Bellamri","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"10.1016\/j.ard.2026.09.015_bib0069","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","article-title":"Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis","volume":"47","author":"Komai","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"17","key":"10.1016\/j.ard.2026.09.015_bib0071","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ard.2026.09.015_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.ard.2026.09.015_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0074","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13928","article-title":"Anti-fibrotic effects of different sources of MSC in bleomycin-induced lung fibrosis in C57BL6 male mice","volume":"26","author":"Periera-Simon","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.ard.2026.09.015_bib0075","article-title":"Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0076","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.09.015_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670637","article-title":"The OX40\/OX40L Axis Regulates T Follicular Helper Cell Differentiation: implications for Autoimmune Diseases","volume":"12","author":"Fu","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.ard.2026.09.015_bib0078","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3899\/jrheum.080120","article-title":"Increased serum soluble OX40 in patients with systemic sclerosis","volume":"35","author":"Komura","year":"2008","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2026.09.015_bib0079","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1007\/s13555-024-01308-8","article-title":"A narrative review of the OX40-OX40L pathway as a potential therapeutic target in atopic dermatitis: focus on rocatinlimab and amlitelimab","volume":"14","author":"Abdelhalim","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"27","key":"10.1016\/j.ard.2026.09.015_bib0080","doi-asserted-by":"crossref","first-page":"E3901","DOI":"10.1073\/pnas.1523512113","article-title":"OX40L blockade protects against inflammation-driven fibrosis","volume":"113","author":"Elhai","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ard.2026.09.015_bib0081","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/23971983241278079","article-title":"Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease","volume":"10","author":"Khanna","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.ard.2026.09.015_bib0082","article-title":"Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"167","key":"10.1016\/j.ard.2026.09.015_bib0083","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"23","key":"10.1016\/j.ard.2026.09.015_bib0084","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1111\/bph.17303","article-title":"PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells","volume":"181","author":"Reininger","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"22","key":"10.1016\/j.ard.2026.09.015_bib0085","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0086","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13075-020-02266-0","article-title":"The role of the oncostatin M\/OSM receptor \u03b2 axis in activating dermal microvascular endothelial cells in systemic sclerosis","volume":"22","author":"Marden","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0087","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/03008207.2018.1500558","article-title":"Oncostatin M and its role in fibrosis","volume":"60","author":"Stawski","year":"2019","journal-title":"Connect Tissue Res"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0088","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/rheumatology\/keac300","article-title":"Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis","volume":"62","author":"Denton","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.09.015_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.ard.2026.09.015_bib0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dot.2022.58.4.3378056","article-title":"Nemolizumab for atopic dermatitis","volume":"58","author":"Labib","year":"2022","journal-title":"Drugs Today (Barc)"},{"issue":"20","key":"10.1016\/j.ard.2026.09.015_bib0091","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ard.2026.09.015_bib0092","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/23971983241291923","article-title":"A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: study design and rationale of the VITALISScE\u2122 study","volume":"10","author":"Khanna","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.ard.2026.09.015_bib0093","unstructured":"Distler O, de Vries-Bouwstra JK, Hoffmann-Vold AM, Kuwana M, Low A, Proudman SM, et al. Results of a Phase II study (VITALISScE) with the soluble guanylate cyclase activator avenciguat. Presented at: EULAR 2026, European Congress of Rheumatology; June 3\u20136, 2026. Abstract POS0566."},{"issue":"8","key":"10.1016\/j.ard.2026.09.015_bib0094","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/art.42858","article-title":"EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis","volume":"76","author":"Egal","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.09.015_bib0095","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/BOR.0000000000000827","article-title":"Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment","volume":"33","author":"Arron","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.09.015_bib0096","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ard.2025.11.021","article-title":"From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosis","volume":"85","author":"Lescoat","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.ard.2026.09.015_bib0097","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ard.2026.09.015_bib0098","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.09.015_bib0099","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/art.42847","article-title":"Myeloablation followed by hematopoietic stem cell transplantation and long-term normalization of systemic sclerosis molecular signatures","volume":"76","author":"Wareing","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726005935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726005935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:53:12Z","timestamp":1792756392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726005935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":99,"alternative-id":["S0003496726005935"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.09.015","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging drugs in phase 2\/3 and selected phase 1\/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}